Multicancer Screening Market to Grow with a CAGR of 15.12% through 2030
Increasing
government initiatives to support cancer screening programs and advancements in
multi-analyte liquid biopsy techniques, is expected to
drive the Global Multicancer Screening Market growth in the forecast period, 2026-2030
According to
TechSci Research report, “Multicancer Screening Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2030F”,
the Global Multicancer Screening Market stood at USD 1.41 Billion in 2024 and is expected to reach USD
3.29 Billion by 2030 with a CAGR of 15.12% during the forecast period. The Global Multicancer Screening Market
is evolving rapidly due to rising investments in precision medicine, the aging
global population, and the increasing emphasis on non-invasive diagnostics. A
growing body of clinical research has shifted the medical paradigm toward
proactive health management, prompting healthcare providers to adopt screening
tests that can identify cancer in asymptomatic individuals. Pharmaceutical and
biotech companies are playing a pivotal role by integrating multicancer
screening into broader oncology care programs. The growing number of
cancer-related deaths has led to the implementation of national screening
programs, driving demand for innovative technologies that can detect multiple
malignancies at once. Strategic acquisitions and partnerships are also fueling
the expansion of technology portfolios among diagnostics firms, enabling faster
commercialization of multicancer detection platforms.
The
market is also shaped by advancements in epigenetics and methylation-based
assays, which have emerged as powerful tools for identifying cancer signatures
across different tumor types. These tests can often determine the tissue of
origin, a critical factor for initiating timely and appropriate treatment.
Another growing trend is the application of wearable health devices and digital
health platforms that gather continuous physiological data, which, when
integrated with MCED technologies, can create comprehensive early warning
systems. Direct-to-consumer testing models are gaining popularity, offering
patients the convenience of home-based blood collection kits and remote test
access. As personalization becomes central to healthcare, tailored screening programs
based on genetic risk profiles and family history are being developed, aligning
with the shift toward individualized cancer management strategies.
Growth
opportunities for the Global Multicancer Screening Market lie in expanding
access to underserved populations through government-led screening campaigns
and subsidies. Collaborations between public health agencies and diagnostics
firms can support mass implementation of low-cost MCED tests, particularly in
low- and middle-income countries where late-stage diagnosis remains a critical
issue. Technological miniaturization and point-of-care testing formats present
untapped potential to bring early cancer detection closer to patients in rural
or resource-limited settings. Regulatory harmonization across markets and the
creation of universal clinical validation protocols can speed up the global
adoption of MCED solutions. Venture capital funding and incentives for
innovation are expected to further encourage the entry of new market players,
fueling healthy competition and fostering breakthroughs in test performance,
accessibility, and affordability.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Multicancer Screening Market”
The Global Multicancer
Screening Market is segmented into test type, technology, sample, method,
cancer type, application, end user, regional distribution, and company.
Based on the Cancer
Type, Gastrointestinal emerged as the fastest growing segment in the Global Multicancer
Screening Market during the forecast period. This is due to the increasing
prevalence of gastrointestinal cancers, such as colorectal, stomach, and
esophageal cancers, and the growing emphasis on early detection. GI cancers are
among the most common types of cancers globally, and their early detection
significantly improves survival rates. As awareness about the importance of
early screening grows, particularly in high-risk populations, there has been a
surge in demand for effective and non-invasive screening solutions for these
cancers. Furthermore, advancements in diagnostic technologies like
Next-Generation Sequencing (NGS) and liquid biopsy have made it easier to
detect genetic mutations and biomarkers associated with gastrointestinal
cancers, making screenings more precise and accessible. The increasing adoption
of these technologies by healthcare providers and growing investments in
research related to GI cancer detection are driving the market's growth in this
segment.
Based
on the Region, Asia-Pacific emerged as the fastest growing region in the Global
Multicancer Screening Market during
the forecast period. This is due to the growing healthcare infrastructure, the
increasing adoption of modern technologies like Next-Generation Sequencing
(NGS) and In-Vitro Diagnostics (IVDs). These technologies are becoming more
affordable and accessible to a wider population, thus enabling a more
comprehensive approach to cancer screening across different types of cancer.
Furthermore, the region is seeing a surge in collaborations between public and
private sectors, with significant investments in research and development for
innovative screening solutions. As a result, countries within Asia-Pacific are
experiencing breakthroughs in cancer detection, making it the fastest growing
region for multicancer screening globally. The rise in healthcare expenditure
and regulatory support for the introduction of new diagnostic technologies is
expected to continue fueling the region’s market growth during the forecast
period.
Major
companies operating in Global Multicancer Screening Market are:
- Agilent
Technologies, Inc.
- Atara
Biotherapeutics, Inc.
- Burning
Rock Biotech Limited
- Exact
Sciences Corporation
- F.
Hoffmann-La Roche Ltd.
- Fulgent
Genetics, Inc.
- Genecast
Biotechnology Co., Ltd.
- Guardant
Health, Inc.
- Illumina,
Inc.
- Konica
Minolta, Inc.
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Global Multicancer Screening Market
is expanding due to the rising prevalence of lifestyle-related cancers. Factors
such as poor diet, sedentary lifestyles, smoking, and alcohol consumption are
leading to an increased incidence of cancers like colorectal, lung, and liver.
As these cancers become more prevalent, there is growing awareness about the
need for early screening and detection to improve survival rates. Public health
initiatives and increased education regarding cancer risk factors are also pushing
the demand for regular screenings. This trend is encouraging healthcare
providers to adopt multicancer screening solutions, driving the growth of the
market. These factors are driving the market in the forecast period.,”
said Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Multicancer Screening
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
Segmented By Test Type (Laboratory Developed Tests (LDTs), In-Vitro Diagnostics
(IVDs)), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction
(PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH),
Others), By Sample (Tissue, Blood, Saliva and Buccal Swab, Others), By Method
(DNA, RNA, Proteins), By Cancer Type (Breast and Gynecologic, Gastrointestinal,
Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological
Malignancies, Lung, Head and Neck, Other Cancer Types), By Application
(Clinical, Research), By End User (Hospitals, Diagnostic and Clinical
Laboratories, Academic Research Institutions, Others), By Region and
Competition, 2020-2030F”, has evaluated the future growth potential of Global
Multicancer Screening Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Multicancer
Screening Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com